The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis
Abstract
BACKGROUND: Theoretically, the everolimus-eluting bioresorbable vascular scaffold (BVS) could eliminate stent thrombosis and improve outcomes in patients having percutaneous coronary intervention. PURPOSE: To estimate the incidence of stent thrombosis after BVS implantation and to compare the efficacy and safety of BVSs versus everolimus-eluting metallic stents (EESs) in adults having percutaneous coronary intervention. DATA SOURCES: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, conference proceedings, and relevant Web sites from inception through 20 January 2016. STUDY SELECTION: 6 randomized, controlled trials and 38 observational studies, each involving at least 40 patients with BVS implantation. DATA EXTRACTION: Two reviewers independently extracted study data and evaluated study risk of bias. DATA SYNTHESIS: The pooled incidence of definite or probable stent thrombosis after BVS implantation was 1.5 events per 100 patient-years (PYs) (95% CI, 1.2 to 2.0 events per 100 PYs) (126 events during 8508 PYs). Six randomized trials that directly compared BVSs with EESs showed a non-statistically significant increased risk for stent thrombosis (odds ratio [OR], 2.05 [CI, 0.95 to 4.43]; P = 0.067) and myocardial infarction (OR, 1.38 [CI, 0.98 to 1.95]; P = 0.064) with BVSs. The 6 observational studies that compared BVSs with EESs showed increased risk for stent thrombosis (OR, 2.32 [CI, 1.06 to 5.07]; P = 0.035) and myocardial infarction (OR, 2.09 [CI, 1.23 to 3.55]; P = 0.007) with BVSs. The relative rates of all-cause and cardiac death, revascularization, and target lesion failure were similar for BVSs and EESs. LIMITATION: Scarce comparative data, no published data from large trials with long-term follow-up, and limited quality and incomplete reporting of observational studies. CONCLUSION: Compared with EESs, BVSs do not eliminate and might increase risks for stent thrombosis and myocardial infarction in adults having percutaneous coronary intervention. Results of large trials with long-term follow-up are critically needed to establish the safety or at least the noninferiority of BVSs compared with EESs. PRIMARY FUNDING SOURCE: None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statin treatment increases circulating PCSK9 serum levels [282], and thus the best effect of these mAbs has been demonstrated in combination with statins.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [282]
In the citing paper
“In some studies an increase of patient-reported neurocognitive effects was described.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [250]
In the citing paper
“In some studies an increase of patient-reported neurocognitive effects was described.This finding requires further scrutiny.250”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [250]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., Detre, K., Veltri, L., Ricci, D., Nobuyoshi, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310802 · Cited by 4,271
Transformations Related to the Angular and the Square Root
Freeman, M. F., & Tukey, J. W. (1950) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729756 · Cited by 2,628
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Serruys, P. W., Ormiston, J. A., Onuma, Y., Regar, E., Gonzalo, N., Garcia-Garcia, H. M., Nieman, K., Bruining, N., Dorange, C., Miquel-Hébert, K., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60325-1 · Cited by 820
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
Ellis, S. G., Kereiakes, D. J., Metzger, D. C., Caputo, R. P., Rizik, D. G., Teirstein, P. S., Litt, M. R., Kini, A., Kabour, A., Marx, S. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509038 · Cited by 630
Nakazawa, G., Finn, A. V., Joner, M., Ladich, E., Kutys, R., Mont, E. K., Gold, H. K., Burke, A. P., Kolodgie, F. D., & Virmani, R. (2008) · Circulation · doi:10.1161/circulationaha.107.762047 · Cited by 611
Research works printed but not linked: 4
- Onuma Y, 2014, Eur Heart J, 35, 982
- Azzalini L, 2015, J Invasive Cardiol, 27, 85
- Robaei D, 2015, J Invasive Cardiol
- Romero M, 2015, Eur Heart J, 36, 649
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Device thrombosis with bioresorbable scaffolds
Mukherjee, D. (2017) · New England Journal of Medicine · doi:10.1056/nejme1703202 · Cited by 22
Metadata
- Authors
- Zhang, X.-L., Zhu, L., Wei, Z.-H., Zhu, Q.-Q., Qiao, J.-Z., Dai, Q., Huang, W., Li, X.-H., Xie, J., Kang, L.-N., Wang, L., & Xu, B.
- Affiliations
- From Affiliated Drum Tower Hospital and Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
- Nanjing General Hospital of Nanjing Military Command (CN)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 752-763
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2418707371
- Cited by
- 31
- References
- 62
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 6 · 2016: 9
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- bioresorbable vascular scaffolds, everolimus-eluting stent, metallic stents, percutaneous coronary intervention, stent thrombosis, myocardial infarction, target lesion failure, revascularization, coronary artery disease, drug-eluting stents, long-term outcomes, cardiovascular mortality, all-cause mortality
- MeSH terms
- Everolimus, Cardiovascular Agents, Cause of Death, Coronary Artery Disease, Humans, Myocardial Infarction, Postoperative Complications, Thrombosis, Absorbable Implants, Tissue Scaffolds, Drug-Eluting Stents, Comparative Effectiveness Research, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.7326/m16-0006
- The paper
- Zhang, X.-L., Zhu, L., Wei, Z.-H., Zhu, Q.-Q., Qiao, J.-Z., Dai, Q., Huang, W., Li, X.-H., Xie, J., Kang, L.-N., Wang, L., & Xu, B. (2016). Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. Annals of Internal Medicine. https://doi.org/10.7326/m16-0006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.